Evidence map›Paper›PMID 32728926›Full record

Observational studyInternational orthopaedics2020

Patient safety associated with the surgical treatment of bone and soft tissue tumours during the COVID-19 pandemic-results from an observational study at the Oxford Sarcoma Service.

Raja Bhaskara Rajasekaran, Sanjeev Kotecha, Duncan Whitwell, Thomas D A Cosker, Paul Critchley, Charles Anton Fries, David Pigott, Christopher L M H Gibbons, Andrew Carr

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in International orthopaedics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Raja Bhaskara RajasekaranThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK. rajalibra299@gmail.com.ORCID 0000-0003-0378-7411
Sanjeev KotechaThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
Duncan WhitwellThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
Thomas D A CoskerThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
Paul CritchleyThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
Charles Anton FriesThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
David PigottThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
Christopher L M H GibbonsThe Oxford Bone and Soft tissue tumour service, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX37LD, UK.
Andrew CarrNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, OX3 7LD, UK.
Nuffield Orthopaedic Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDeferring cancer surgery can have profound adverse effects including patient mortality. During the COVID-19 pandemic, departmental reorganisation and adherence to evolving guidelines enabled provision of uninterrupted surgical care to patients with bone and soft tissue tumours (BST) in need of surgery. We reviewed the outcomes of surgeries on BST during the first two months of the pandemic at one of the tertiary BST centres in the UK. MATERIALS AND

methodsBetween 12 March 2020 and 12 May 2020, 56 patients of a median age of 57 years (18-87) underwent surgery across two sites: index hospital (n = 27) and COVID-free facility (n = 29). Twenty-five (44.6%) patients were above the age of 60 years and 20 (35.7%) patients were in ASA III and ASA IV category. The decision to offer surgery was made in adherence with the guidelines issued by the NHS, BOOS and BSG.

resultsAt a minimum follow-up of 30 days post-surgery, 54 (96.4%) patients were recovering well. Thirteen patients (23.2%) had post-operative complications which included four (7.1%) patients developing pulmonary embolism. The majority of complications (12/13 = 92.7%) occurred in ASA III and IV category patients. Four (7.1%) patients contracted COVID-19, of which three required escalation of care due to pulmonary complications and two (3.6%) died. Patients < 60 years of age had significantly less complications than those > 60 years (p < 0.001). Patients operated on in the COVID-free facility had fewer complications compared with those operated on at the index hospital (p < 0.027).

conclusionIn spite of the favourable results in majority of our patients, our study shows that patients with sarcoma operated at the height of the pandemic are at a risk of contracting COVID-19 and also having associated with mortality. The use of a COVID-free facility, surgery in patients < 60 60 years and in ASA I & II category are associated with better outcomes. If a second wave occurs, a serious consideration should be given to ways of minimising the risk of contracting COVID-19 in these vulnerable patients either by using COVID-free facilities or delaying treatment until peak of infection has passed.

Indexed as

COVID-19PandemicsPatient SafetyAdolescentAdultAgedAged, 80 and overBone NeoplasmsFemaleHumansMaleMiddle AgedSarcomaSARS-CoV-2Soft Tissue NeoplasmsYoung AdultBone tumourCancer surgeryCOVID-19Sarcoma

Identifiers

PMID32728926
PMCPMC7387417
OpenAlexW3045834079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.